One CEO comes out and states how biotech will be the new focus for Glaxo, as in a related story whereby patients will require genetic testing for their AIDS drug, Ziagen. In the future I’m sure there will be more about big pharma and their biotech strategies as personalized medicine continues...
The recent turn of events has literally put the FDA on somewhat of a hot seat... for an agency that minimally invested in technology, compared to other government entities, it is finding itself in a position of having to play "catch up" in a hurry...as evidenced with the recent turn of events...